Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ibrahim Aldoss

Showing results (1-10 of 233) with videos related to

Pageof 24
Sort By:
Clinical Advances in Hematology & Oncology : H&O|February 5, 2025
Chimeric antigen receptor T-cell therapy for T-cell acute lymphocytic leukemiaIbrahim Aldoss
The Lancet. Haematology|July 5, 2023
More opportunities to advance paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemiaLindsey Murphy, Ibrahim Aldoss
Chinese Clinical Oncology|November 6, 2019
More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabineIbrahim Aldoss, Guido Marcucci
Clinical Lymphoma, Myeloma & Leukemia|May 18, 2026
Measurable Residual Disease and Its Management in Adult Acute Lymphoblastic LeukemiaTamer Othman, Ibrahim Aldoss
Blood|January 25, 2020
How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemiaIbrahim Aldoss, Dan Douer
Translational Pediatrics|April 9, 2024
Blinatumomab improves outcomes for pediatric patients with low-risk B-cell acute lymphoblastic leukemia in first marrow relapseLindsey Murphy, Ibrahim Aldoss
Haematologica|April 16, 2026
Refining post-blinatumomab risk stratification through ultrasensitive-based measurable residual disease assessmentYazeed Samara, Ibrahim Aldoss
Leukemia Research|October 4, 2012
Therapy-related acute myeloid leukemia with favorable cytogenetics: still favorable?Ibrahim Aldoss, Vinod Pullarkat
Blood|December 4, 2025
Donor-derived CD7 CAR-T in T-ALL/LBL: promise and pitfallsIbrahim Aldoss, Lori Muffly
Chinese Clinical Oncology|July 11, 2023
Searching for the optimal sequence of dual-targeted CAR T cells in relapsed/refractory acute lymphoblastic leukemiaVaibhav Agrawal, Ibrahim Aldoss
Pageof 24

Showing results (1-10 of 233) with videos related to

Sort By:
Pageof 24
Clinical Advances in Hematology & Oncology : H&O|February 5, 2025
Chimeric antigen receptor T-cell therapy for T-cell acute lymphocytic leukemiaIbrahim Aldoss
The Lancet. Haematology|July 5, 2023
More opportunities to advance paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemiaLindsey Murphy, Ibrahim Aldoss
Chinese Clinical Oncology|November 6, 2019
More options for older patients with acute myeloid leukemia: venetoclax in combination with low dose cytarabineIbrahim Aldoss, Guido Marcucci
Clinical Lymphoma, Myeloma & Leukemia|May 18, 2026
Measurable Residual Disease and Its Management in Adult Acute Lymphoblastic LeukemiaTamer Othman, Ibrahim Aldoss
Blood|January 25, 2020
How I treat the toxicities of pegasparaginase in adults with acute lymphoblastic leukemiaIbrahim Aldoss, Dan Douer
Translational Pediatrics|April 9, 2024
Blinatumomab improves outcomes for pediatric patients with low-risk B-cell acute lymphoblastic leukemia in first marrow relapseLindsey Murphy, Ibrahim Aldoss
Haematologica|April 16, 2026
Refining post-blinatumomab risk stratification through ultrasensitive-based measurable residual disease assessmentYazeed Samara, Ibrahim Aldoss
Leukemia Research|October 4, 2012
Therapy-related acute myeloid leukemia with favorable cytogenetics: still favorable?Ibrahim Aldoss, Vinod Pullarkat
Blood|December 4, 2025
Donor-derived CD7 CAR-T in T-ALL/LBL: promise and pitfallsIbrahim Aldoss, Lori Muffly
Chinese Clinical Oncology|July 11, 2023
Searching for the optimal sequence of dual-targeted CAR T cells in relapsed/refractory acute lymphoblastic leukemiaVaibhav Agrawal, Ibrahim Aldoss
Pageof 24